Home Journals Articles Updates About
CN
image
收藏切换
Tumor immune checkpoint therapy and the drug delivery strategies
收藏切换
PDF
Pei-shan LI, Yi-xuan LIU, Ying XIE, Yu-xin REN, Ming CHEN, Gui-ling WANG, Wan-liang LÜ*
Acta Pharmaceutica Sinica | 2022, 57(1) : 13 - 24
Less
收藏切换
Acta Pharmaceutica Sinica | 2022, 57(1): 13-24
• Reviews •
Tumor immune checkpoint therapy and the drug delivery strategies
Full
Pei-shan LI, Yi-xuan LIU, Ying XIE, Yu-xin REN, Ming CHEN, Gui-ling WANG, Wan-liang LÜ*
Affiliations
  • State Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Molecular Pharmaceutics and Drug Delivery System, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
Published: 2022-01-12 doi: 10.16438/j.0513-4870.2021-1150
Outline
收藏切换

Tumor immune checkpoint therapy is a clinical treatment strategy developed based on the new principle of the inhibition of negative immune regulation. In this article, the tumor immune checkpoint therapy and the drug delivery strategies were reviewed, mainly including immunity and tumor therapy, tumor immune checkpoint therapy and its mechanism of action, clinical application of tumor immune checkpoint therapy and therapeutic drugs, immune resistance of programmed cell death protein 1 (PD1)/programmed cell death ligand 1 (PDL1) treatment and countermeasures, drug delivery strategies for tumor immune checkpoint therapeutic agents, etc. As a revolutionary new immunotherapy strategy, tumor immune checkpoint therapy has shown obvious superior therapeutic efficacy in a variety types of tumor. However, tumor immune checkpoint therapy is also faced with a big challenge, namely, immunotherapy resistance. With the discovery of new mechanism, the continuous development of new therapeutic drugs and delivery strategies, tumor immune checkpoint therapy is expected to further improve the clinical efficacy of tumor.

neoplasm  /  immune checkpoint inhibitor  /  immune tolerance  /  programmed cell death protein 1/programmed cell death ligand 1  /  drug delivery system
Pei-shan LI, Yi-xuan LIU, Ying XIE, Yu-xin REN, Ming CHEN, Gui-ling WANG, Wan-liang LÜ. Tumor immune checkpoint therapy and the drug delivery strategies[J]. Acta Pharmaceutica Sinica, 2022 , 57 (1) : 13 -24 . DOI: 10.16438/j.0513-4870.2021-1150
Appendix
Less
Year 2022 volume 57 Issue 1
PDF
207
89
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2021-1150
  • Receive Date：2021-08-06
  • Online Date：2025-12-22
  • Published：2022-01-12
Article Data
Affiliations
History
  • Received：2021-08-06
  • Revised：2021-09-06
Funding
Affiliations
    State Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Molecular Pharmaceutics and Drug Delivery System, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2021-1150
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House